Crossover trials are only useful when there is a positive correlation between the response to different treatment modalities

被引:11
作者
Cleophas, TJM
机构
[1] Department of Medicine, Merwede Hospital, Dordrecht
[2] Department of Medicine, Merwede Hospital, Dordrecht, 3360 AB Sliedrecht
关键词
crossover design; parallel groups design; correlation between treatment modalities; statistical assessment; statistical power; negative correlations; a priori estimates of correlation;
D O I
10.1111/j.1365-2125.1996.tb00188.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Trials that do not allow us to reject the null hypothesis of no treatment effect may have had an inappropriate design. Trials are virtually never assessed for correlation between responses to different treatment modalities. 2 The level of correlation between responses to different treatment modalities is a major determinant of the power of crossover trials. 3 It is relevant to assess correlation levels between responses to the different treatment modalities a priori. With a negative correlation a crossover design is likely to lack power. 4 In 1991 the British Journal of Clinical Pharmacology published eight crossover trials which would have been more efficient had they been performed with a parallel groups design.
引用
收藏
页码:235 / 239
页数:5
相关论文
共 10 条
[1]  
ARMITAGE P, 1995, BR J CLIN PHARM, V32, P1
[2]   CLINICAL-TRIALS IN CHRONIC DISEASES [J].
CLEOPHAS, TJM ;
TAVENIER, P .
JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (06) :594-598
[3]  
Cleophas Ton J.M., 1994, Am J Ther, V1, P327, DOI 10.1097/00045391-199412000-00013
[4]   PUBLICATION BIAS IN CLINICAL RESEARCH [J].
EASTERBROOK, PJ ;
BERLIN, JA ;
GOPALAN, R ;
MATTHEWS, DR .
LANCET, 1991, 337 (8746) :867-872
[5]   A CRITIQUE OF RECENT RESEARCH ON THE 2-TREATMENT CROSSOVER DESIGN [J].
FLEISS, JL .
CONTROLLED CLINICAL TRIALS, 1989, 10 (03) :237-243
[6]   THE PERFORMANCE OF THE 2-STAGE ANALYSIS OF 2-TREATMENT, 2-PERIOD CROSSOVER TRIALS [J].
FREEMAN, PR .
STATISTICS IN MEDICINE, 1989, 8 (12) :1421-1432
[7]  
Grieve A P, 1994, Stat Methods Med Res, V3, P407, DOI 10.1177/096228029400300406
[8]   2-PERIOD CHANGE-OVER DESIGN AND ITS USE IN CLINICAL TRIALS [J].
GRIZZLE, JE .
BIOMETRICS, 1965, 21 (02) :467-&
[9]  
MCLEODS RES, 1986, LANCET, V1, P727
[10]   PROBLEMS WITH THE 2 STAGE ANALYSIS OF CROSSOVER TRIALS [J].
SENN, SJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (01) :133-133